Lupin receives FDA approval for generic Axiron topical solution
27 October 2017 | News
Lupin’s Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company’s Axiron Topical Solution, 30 mg per actuation
Source: Pixabay
Pharma Major Lupin has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s Axiron® Topical Solution, 30 mg per actuation.
Lupin’s Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company’s Axiron® Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Testosterone Topical Solution, 30 mg per actuation, had annual sales of approximately USD 244.2 million in the US. (IMS MAT June 2017).
